Skip to main content
Journal cover image

Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study.

Publication ,  Journal Article
Feng, T; Howard, LE; Vidal, AC; Moreira, DM; Castro-Santamaria, R; Andriole, GL; Freedland, SJ
Published in: International journal of urology : official journal of the Japanese Urological Association
February 2017

To determine if cholesterol is a risk factor for the development of lower urinary tract symptoms in asymptomatic men.A post-hoc analysis of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study was carried out in 2323 men with baseline International Prostate Symptom Score <8 and not taking benign prostatic hyperplasia or cholesterol medications. Cox proportion models were used to test the association between cholesterol, high-density lipoprotein, low-density lipoprotein and the cholesterol : high-density lipoprotein ratio with incident lower urinary tract symptoms, defined as first report of medical treatment, surgery or two reports of an International Prostate Symptom Score >14.A total of 253 men (10.9%) developed incident lower urinary tract symptoms. On crude analysis, higher high-density lipoprotein was associated with a decreased lower urinary tract symptoms risk (hazard ratio 0.89, P = 0.024), whereas total cholesterol and low-density lipoprotein showed no association. After multivariable adjustment, the association between high-density lipoprotein and incident lower urinary tract symptoms remained significant (hazard ratio 0.89, P = 0.044), whereas no association was observed for low-density lipoprotein (P = 0.611). There was a trend for higher cholesterol to be linked with higher lower urinary tract symptoms risk, though this was not statistically significant (hazard ratio 1.04, P = 0.054). A higher cholesterol : high-density lipoprotein ratio was associated with increased lower urinary tract symptoms risk on crude (hazard ratio 1.11, P = 0.016) and adjusted models (hazard ratio 1.12, P = 0.012).Among asymptomatic men participating in the REDUCE study, higher cholesterol was associated with increased incident lower urinary tract symptoms risk, though the association was not significant. A higher cholesterol : high-density lipoprotein ratio was associated with increased incident lower urinary tract symptoms, whereas higher high-density lipoprotein was protective. These findings suggest dyslipidemia might play a role in lower urinary tract symptoms progression.

Duke Scholars

Published In

International journal of urology : official journal of the Japanese Urological Association

DOI

EISSN

1442-2042

ISSN

0919-8172

Publication Date

February 2017

Volume

24

Issue

2

Start / End Page

151 / 156

Related Subject Headings

  • Urology & Nephrology
  • Risk Factors
  • Prostatic Neoplasms
  • Prostatic Hyperplasia
  • Middle Aged
  • Male
  • Lower Urinary Tract Symptoms
  • Longitudinal Studies
  • Incidence
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Feng, T., Howard, L. E., Vidal, A. C., Moreira, D. M., Castro-Santamaria, R., Andriole, G. L., & Freedland, S. J. (2017). Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study. International Journal of Urology : Official Journal of the Japanese Urological Association, 24(2), 151–156. https://doi.org/10.1111/iju.13265
Feng, Tom, Lauren E. Howard, Adriana C. Vidal, Daniel M. Moreira, Ramiro Castro-Santamaria, Gerald L. Andriole, and Stephen J. Freedland. “Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study.International Journal of Urology : Official Journal of the Japanese Urological Association 24, no. 2 (February 2017): 151–56. https://doi.org/10.1111/iju.13265.
Feng T, Howard LE, Vidal AC, Moreira DM, Castro-Santamaria R, Andriole GL, et al. Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study. International journal of urology : official journal of the Japanese Urological Association. 2017 Feb;24(2):151–6.
Feng, Tom, et al. “Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study.International Journal of Urology : Official Journal of the Japanese Urological Association, vol. 24, no. 2, Feb. 2017, pp. 151–56. Epmc, doi:10.1111/iju.13265.
Feng T, Howard LE, Vidal AC, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ. Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study. International journal of urology : official journal of the Japanese Urological Association. 2017 Feb;24(2):151–156.
Journal cover image

Published In

International journal of urology : official journal of the Japanese Urological Association

DOI

EISSN

1442-2042

ISSN

0919-8172

Publication Date

February 2017

Volume

24

Issue

2

Start / End Page

151 / 156

Related Subject Headings

  • Urology & Nephrology
  • Risk Factors
  • Prostatic Neoplasms
  • Prostatic Hyperplasia
  • Middle Aged
  • Male
  • Lower Urinary Tract Symptoms
  • Longitudinal Studies
  • Incidence
  • Humans